Based on the results of the Phase 2 Study 191622-130 \[NCT02010775\], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90 as Assessed by the Investigator
Timeframe: Day 90
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Timeframe: First dose (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Systolic Blood Pressure
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Diastolic Blood Pressure
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Respiratory Rate
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Pulse Rate
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180) ]